Abulhassan Ali, Faris Abu Za’nouneh, Collin Clarke, Shunsuke Kondo, Christian John S Capirig, Ehab G Daoud
Cite
Ali A, Abu Za’nouneh F, Clarke C, Kondo S, Capirig CJS, Daoud EG. Transfusion-Related Acute Lung Injury: A comprehensive review with a focus on the critically ill, and future directions in diagnostic approach. J Mech Vent 2025; 6(4):169-180.
Abstract
Transfusion-related acute lung injury (TRALI) is a severe, life-threatening complication of blood products transfusion characterized by acute hypoxemia and non-cardiogenic pulmonary edema, typically within six hours following transfusion of blood products. It is a highly morbid complication in critically ill patients, particularly those with pre-existing lung injury or systemic inflammation. TRALI remains frequently under-reported due to diagnostic challenges, mainly attributable to the absence of validated confirmatory tests, resulting in diagnostic uncertainty, delayed recognition, and unfavorable clinical outcomes.
The present review represents an extensive literature search for evidence related to the diagnostic utility of novel biomarkers, including interleukin-8, soluble intracellular adhesion molecules, and a review of existing data on management strategies in the critical care setting, including the role of mechanical ventilation, non-invasive ventilation, and the potential roles of immunomodulatory therapies. Through a focused lens on critically ill populations, this review aims to clarify the current TRALI diagnosis and management landscape while highlighting areas for ongoing investigation.
Keywords: Transfusion-related acute lung injury (TRALI), biomarker, mechanical ventilation, critically ill
References
| 1. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood 2019; 133(17):1840-1853. https://doi.org/10.1182/blood-2018-10-860809 PMid:30808638 | |||
| 2. Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. British Journal of Haematology 2009; 147(4):431-443. https://doi.org/10.1111/j.1365-2141.2009.07840.x PMid:19663827 PMCid:PMC4532338 | |||
| 3. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med 1951; 51(20):2399-2402. | |||
| 4. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44(12):1774-1789. https://doi.org/10.1111/j.0041-1132.2004.04347.x PMid:15584994 | |||
| 5. Fatalities reported to FDA following blood collection and transfusion annual summary for FY2021. https://www.fda.gov/media/172382/download | |||
| 6. Kumar R, Sedky MJ, Varghese SJ, et al. Transfusion related acute lung injury (TRALI): A single institution experience of 15 years. Indian J Hematol Blood Transfus 2015; 32(3):320-327. https://doi.org/10.1007/s12288-015-0604-4 PMid:27429525 PMCid:PMC4930763 | |||
| 7. Gajic O, Rana R, Winters JL, et al. Transfusion-related Acute Lung Injury in the critically Ill. Am J Respir Crit Care Med 2007; 176(9):886-891 https://doi.org/10.1164/rccm.200702-271OC PMid:17626910 PMCid:PMC2048675 | |||
| 8. Silliman CC, Ambruso DR, Bushkov LK. Transfusion-related acute lung injury. Blood 2005; 105:2266-2273. https://doi.org/10.1182/blood-2004-07-2929 PMid:15572582 | |||
| 9. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573-577. https://doi.org/10.1046/j.1537-2995.1985.25686071434.x PMid:4071603 | |||
| 10. Wallis JP, Lubenko A, Wells AW, et al. Single hospital experience of TRALI. Transfusion 2003; 43(8):583-590. https://doi.org/10.1046/j.1537-2995.2003.00466.x PMid:12869110 | |||
| 11. Kopko PM, Marshall CS, MacKenzie MR, et al. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287(15): 1968-1971. https://doi.org/10.1001/jama.287.15.1968 PMid:11960539 | |||
| 12. Vlaar APJ, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill; A nested case-control study. Crit Care Med 2010; 38(3):771-778. https://doi.org/10.1097/CCM.0b013e3181cc4d4b PMid:20035217 | |||
| 13. Kuldanek SA, Kelher M, Silliman CC. Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update. Expert Rev Hematol 2019; 12(9):773-785. https://doi.org/10.1080/17474086.2019.1640599 PMid:31282773 PMCid:PMC6715498 | |||
| 14. Middelburg RA, Stein DV, Zupanska B, et al. Female donors and transfusion‐related acute lung injury. Transfusion 2010; 50(11):2447-2454. https://doi.org/10.1111/j.1537-2995.2010.02715.x PMid:20529001 PMCid:PMC3740332 | |||
| 15. Cho MS, Modi P, Sharma S. Transfusion Related Acute Lung Injury. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan 2025. Last updated September 15, 2023. | |||
| 16. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119(7):1757-1767. https://doi.org/10.1182/blood-2011-08-370932 PMid:22117051 PMCid:PMC3286351 | |||
| 17. Vlaar APJ, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013; 382(9896):984-994. https://doi.org/10.1016/S0140-6736(12)62197-7 PMid:23642914 | |||
| 18. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an in vivo rat model. J Clin Invest 1998; 101(7):1458-1467. https://doi.org/10.1172/JCI1841 PMid:9525989 PMCid:PMC508724 | |||
| 19. Bux J, Sachs UJH. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136(6):788-799. https://doi.org/10.1111/j.1365-2141.2007.06492.x PMid:17341264 | |||
| 20. Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119(11):3450-3461. https://doi.org/10.1172/JCI38432 PMid:19809160 PMCid:PMC2769181 | |||
| 21. Kuebler WM, William N, Post M, et al. Extracellular vesicles: effectors of transfusion-related acute lung injury. Am J Physiol-Lung Cell Mol Physiol 2023; 325(3):L327-L341. https://doi.org/10.1152/ajplung.00040.2023 PMid:37310760 | |||
| 22. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury A review. Chest 2004; 126(1):249-258. https://doi.org/10.1378/chest.126.1.249 PMid:15249468 | |||
| 23. Velden S van der, Osch TLJ van, Seghier A, et al. Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs. Blood 2024 ;143(1):79-91. https://doi.org/10.1182/blood.2023020484 PMid:37801721 | |||
| 24. Toy P, Popovsky MA, Abraham E, et al; National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33(4):721-726. https://doi.org/10.1097/01.CCM.0000159849.94750.51 PMid:15818095 | |||
| 36. Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin Proc 2005; 80(6):766-770. https://doi.org/10.1016/S0025-6196(11)61531-0 PMid:15945528 | |||
| 37. Şahutoğlu C, Balcı C, Balcıoğlu T. Transfusion-related acute lung injury and treatment with high-flow oxygen therapy in a pediatric patient: a case report. Braz J Anesthesiol 2024; 74(5):744339. https://doi.org/10.1016/j.bjane.2021.12.001 PMid:34929220 PMCid:PMC11440078 | |||
| 38. Frat J P, Thille AW, Mercat A, et al.; FLORALI Study Group; REVA Network. High flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372(23):2185-2196. https://doi.org/10.1056/NEJMoa1503326 PMid:25981908 | |||
| 39. Looney MR, Roubinian N, Gajic O, et al. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury. Crit Care Med 2014; 42(7):1676-1687. https://doi.org/10.1097/CCM.0000000000000323 PMid:24776608 PMCid:PMC4284060 | |||
| 40. Goldberg AD, Kor DJ. State of the art management of transfusion-related acute lung injury (TRALI). Curr Pharm Des 2012; 18(22):3273-3284. https://doi.org/10.2174/1381612811209023273 PMid:22621274 | |||
| 41. Müller MC, Tuinman PR, van der Sluijs KF, et al. Methylprednisolone fails to attenuate lung injury in a mouse model of transfusion related acute lung injury. Transfusion 2014; 54(4):996-1001. https://doi.org/10.1111/trf.12394 PMid:24032748 | |||
| 42. Semple JW, McVey MJ, Kim M, et al. Targeting transfusion-related acute lung injury: the journey from basic science to novel therapies. Crit Care Med 2018; 46(5):e452-e458. https://doi.org/10.1097/CCM.0000000000002989 PMid:29384784 | |||
| 43. Kapur R, Kim M, Rebetz J, et al. Low levels of interleukin-10 in patients with transfusion-related acute lung injury. Ann Transl Med; 5(16):339. https://doi.org/10.21037/atm.2017.04.37 PMid:28861436 PMCid:PMC5566739 | |||
| 44. Kapur R, Kim M, Aslam R, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood 2017; 129(18):2557-2569. https://doi.org/10.1182/blood-2016-12-758185 PMid:28202460 PMCid:PMC5418638 | |||
| 45. Guo K, Ma S. The immune system in transfusion-related acute lung injury prevention and therapy: update and perspective. Front Mol Biosci 2021; 8:639976. https://doi.org/10.3389/fmolb.2021.639976 PMid:33842545 PMCid:PMC8024523 | |||
| 46. Semple JW, Kim M, Hou J, et al. Intravenous immunoglobulin prevents murine antibody mediated acute lung injury at the level of neutrophil reactive oxygen species production. PLoS One 2012; 7(2):e31357. https://doi.org/10.1371/journal.pone.0031357 PMid:22363629 PMCid:PMC3281967 | |||
| 47. Quest GR, Gaal H, Clarke G, et al. Transfusion-related acute lung injury after transfusion of pooled immune globulin: a case report. Transfusion 2014; 54(12):3088-3091. https://doi.org/10.1111/trf.12731 PMid:24898568 | |||
| 48. Rizk A, Gorson KC, Kenney L, et al. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001; 41(2):264-268. https://doi.org/10.1046/j.1537-2995.2001.41020264.x PMid:11239233 | |||
| 49. Baudel JL, Vigneron C, Pras-Landre V, et al. Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clin Rheumatol 2020; 39:541-546. https://doi.org/10.1007/s10067-019-04832-7 PMid:31760541 | |||
| 50. Stoclin A, Delbos F, Dauriat G, et al. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. Vox Sang 2013; 104(2):175-178. https://doi.org/10.1111/j.1423-0410.2012.01645.x PMid:22985417 | |||
| 51. Reddy DRS, Guru PK, Blessing MM, et al. Transfusion-related acute lung injury after IVIG for myasthenic crisis. Neurocrit Care 2015;23(2):259-261. https://doi.org/10.1007/s12028-015-0115-z PMid:25678454 | |||
| 52. Kapur R, Kim M, Shanmugabhavananthan S, et al. C-reactive protein enhances murine antibody-mediated transfusion-related acute lung injury. Blood 2015; 126:2747-2751. https://doi.org/10.1182/blood-2015-09-672592 PMid:26453659 | |||
| 53. Tung JP, Chiaretti S, Dean MM, et al. Transfusion-related acute lung injury (TRALI): potential pathways of development, strategies for prevention and treatment, and future research directions. Blood Rev 2022;53:100926. https://doi.org/10.1016/j.blre.2021.100926 PMid:35065815 | |||
| 54. Tung JP, Fung YL, Nataatmadja M, et al. A novel in vivo ovine model of transfusion-related acute lung injury (TRALI). Vox Sang 2011; 100(2):219-230. https://doi.org/10.1111/j.1423-0410.2010.01381.x PMid:20667072 | |||
| 55. Tung JP, Fraser JF, Nataatmadja M, et al. Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI). Crit Care 2012; 16:R19. https://doi.org/10.1186/cc11178 PMid:22297161 PMCid:PMC3396258 | |||
| 56. Mulder HD, Augustijn QJ, van Woensel JB, et al. Incidence, risk factors, and outcome of transfusion-related acute lung injury in critically ill children: a retrospective study. J Crit Care 2015; 30:55-9. https://doi.org/10.1016/j.jcrc.2014.10.005 PMid:25457117 | |||
| 57. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. Engl J Med 1999; 340(6):409-417. https://doi.org/10.1056/NEJM199902113400601 PMid:9971864 | |||
| 58. Sadaka F, Aggu-Sher R, Krause K, et al. The effect of red blood cell transfusion on tissue oxygenation and microcirculation in severe septic patients. Ann Intensive Care 2011 ;1(1):46. https://doi.org/10.1186/2110-5820-1-46 PMid:22067279 PMCid:PMC3256106 | |||
| 59. Zimmerman R, Tsai AG, Salazar Vázquez BY, et al. Posttransfusion increase of hematocrit per se does not improve circulatory oxygen delivery due to increased blood viscosity. Anesth Analg 2017; 124(5):1547-1554. https://doi.org/10.1213/ANE.0000000000002008 PMid:28328758 PMCid:PMC5654531 | |||
| 60. Coz Yataco AO, Soghier I, Hébert PC, et al. Red blood cell transfusion in critically ill adults: an American College of Chest Physicians clinical practice guideline. Chest 2025; 167(2):477-489. https://doi.org/10.1016/j.chest.2024.09.016 PMid:39341492 PMCid:PMC11867898 | |||
| 61. Luk C, Eckert KM, Barr RM, et al. Prospective audit of the use of fresh-frozen plasma, based on Canadian Medical Association transfusion guidelines. CMAJ 2002; 166(12):1539-1540. | |||
| 62. Lauzier F, Cook D, Griffith L, et al. Fresh frozen plasma transfusion in critically ill patients. Crit Care Med 2007; 35(7):1655-1659. https://doi.org/10.1097/01.CCM.0000269370.59214.97 PMid:17522577 |
